Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 1000+

1. 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events Journal of the American Academy of Dermatology · 2023
2. Hidradenitis suppurativa and major adverse cardiac events: A systematic review and meta-analysis Journal of The American Academy of Dermatology · 2020 · 7 citations
3. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications Advances in Therapy · 2023 · 6 citations
4. PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS? 2022
5. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials 2022 · 25 citations
6. Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program American Journal of Clinical Dermatology · 2025 · 1 citations
7. Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2025
8. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
9. ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW International Journal of Innovative Technologies in Social Science · 2025
10. JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study Dermatology and Therapy · 2026 · 1 citations

Community

— no results